The spatial and temporal distribution of cancer driver events across tumor subclones directly influences how tumors respond to therapeutic interventions and shapes their evolutionary trajectories. Mapping these driver events within subclones can reveal the historical accumulation patterns of oncogenic mutations and inform treatment strategies. [@hiley_deciphering_2014]
Definitions
- driver events
- subclone
- cancer
- mutation
- therapy response
- tumor evolution
- oncogenic
- temporal distribution
- tumor
- tumors
Synthesis
Subclonal driver events, which confer selective advantages to cancer cells through genetic or molecular alterations, fundamentally shape how tumors respond to therapy and evolve over time through their spatial and temporal heterogeneity. Multiple studies establish that tumors contain distinct subclonal populations with varying driver mutations distributed across different regions and time points, creating complex evolutionary landscapes where specific adaptations like Stat1 inactivation in aneuploid cancers or variable hypoxia responses in glioblastoma represent solutions to fitness challenges. The mechanistic relationship between subclonal architecture and clinical outcomes is bidirectional: driver events present in only some subclones can determine whether therapy succeeds or fails, while simultaneously, understanding this heterogeneity enables improved clinical trial design through better patient stratification. What remains contested is the relative importance of particular driver pathways, as exemplified by the finding that p53 loss is common but not specifically enriched in chromosomally unstable tumors, while Stat1 inactivation combined with increased Myc activity appears selectively favored in this context, suggesting that not all frequent oncogenic events are equally relevant to specific evolutionary trajectories.
Related
- Stat1 inactivation mechanism is conserved between mouse and human aneuploid cancers
- Chromosomal instability promotes immune cell infiltration into tumors
- Hypoxia-related transcriptional programs are variably expressed in glioblastoma cells
- Resolving subclonal heterogeneity improves clinical trial design
- Aneuploid cancers inactivate Stat1 to circumvent immune surveillance
- Aneuploid tumors inactivate Stat1 signaling with increased Myc activity
- p53 loss is common but not enriched in chromosomally unstable tumors
- Tumors contain multiple subclones with spatial and temporal heterogeneity